{"id":22,"date":"2007-12-27T18:25:40","date_gmt":"2007-12-27T17:25:40","guid":{"rendered":"http:\/\/physiologie.envt.fr\/masterpharmaco\/contenus-des-ue-obligatoires\/"},"modified":"2017-06-19T08:44:01","modified_gmt":"2017-06-19T06:44:01","slug":"contenus-des-ue-obligatoires","status":"publish","type":"page","link":"https:\/\/physiologie.envt.fr\/masterpharmaco\/contenus-des-ue-obligatoires\/","title":{"rendered":"Contenus des UE obligatoires"},"content":{"rendered":"<p><em>UE 1<\/em> : <strong>D\u00e9veloppement et \u00e9valuation d&rsquo;un m\u00e9dicament<\/strong><br \/>\n\u2014\u00a050h, 3 ECTS<br \/>\n\u2014\u00a0Cibles pharmacologiques ;<br \/>\n\u2014\u00a0Pr\u00e9requis aux essais cliniques (toxicit\u00e9, reproduction, mod\u00e8les animaux &#8230;)<br \/>\n\u2014\u00a0Aspects m\u00e9thodologiques de base (plan experimental, crit\u00e8res de jugement, population, analyse des r\u00e9sultats&#8230;)<br \/>\n\u2014\u00a0Etudes de phase I, II et III ;<br \/>\n\u2014\u00a0Statistique inf\u00e9rentielle ;<br \/>\n\u2014\u00a0Etudes de phase IV (Pharmacovigilance, Evaluation du potentiel de d\u00e9pendance des m\u00e9dicaments, Pharmaco-\u00e9pid\u00e9miologie ; Evaluation du risque chez la femme enceinte ; Pharmaco-\u00e9conomie)<\/p>\n<p><em>UE 2<\/em> : <strong>Pharmacocin\u00e9tique et pharmacodynamie g\u00e9n\u00e9rales<\/strong><br \/>\n\u2014\u00a050 h, 3 ECTS<br \/>\n\u2014\u00a0Approche physiologique en pharmacocin\u00e9tique (ADME) ; Sch\u00e9mas posologiques ; Relations pharmacocin\u00e9tique-pharmacodynamique ; Pharmacog\u00e9n\u00e9tique ; Bio\u00e9quivalence ; Pharmacocin\u00e9tique non lin\u00e9aire ; Introduction \u00e0 la pharmacocin\u00e9tique de population ; Protocoles de pharmacocin\u00e9tique clinique.<\/p>\n<p><em>UE 3<\/em> : <strong>Aspects r\u00e9glementaires et ateliers pratiques<\/strong><br \/>\n\u2014\u00a050 h, 3 ECTS<br \/>\n\u2014\u00a0R\u00e9glementation et \u00e9thique (Directive Europ\u00e9enne et loi Huriet modifi\u00e9e ; R\u00f4le du CPP ; Recherche et \u00e9thique )<br \/>\n\u2014\u00a0Autorit\u00e9s de sant\u00e9, et proc\u00e9dures d\u2019enregistrement nationales et internationales ;<br \/>\n\u2014\u00a0La recherche institutionelle (point de vue du CHU promoteur, point de vue de la DRC)<br \/>\n\u2014\u00a0Les m\u00e9tiers de l\u2019industrie<br \/>\n\u2014\u00a0Les prestataires de la recherche clinique<br \/>\n\u2014\u00a0Le r\u00f4le de l\u2019investigateur<br \/>\n\u2014\u00a0Cadre juridique de l\u2019information du m\u00e9dicament<br \/>\n\u2014\u00a0Atelier 1 (cours, TD) : Comment aborder un protocole d\u2019essai pharmacologique, exemple de r\u00e9daction d\u2019un protocole<br \/>\n\u2014\u00a0Atelier 2 (cours, TD) : Comment effectuer un recueil de donn\u00e9es, exemple de r\u00e9daction d\u2019un CRF<br \/>\n\u2014\u00a0Pharmacologie Sociale<\/p>\n","protected":false},"excerpt":{"rendered":"<p>UE 1 : D\u00e9veloppement et \u00e9valuation d&rsquo;un m\u00e9dicament \u2014\u00a050h, 3 ECTS \u2014\u00a0Cibles pharmacologiques ; \u2014\u00a0Pr\u00e9requis aux essais cliniques (toxicit\u00e9, reproduction, mod\u00e8les animaux &#8230;) \u2014\u00a0Aspects m\u00e9thodologiques de base (plan experimental, crit\u00e8res de jugement, population, analyse des r\u00e9sultats&#8230;) \u2014\u00a0Etudes de phase I, &hellip; <a href=\"https:\/\/physiologie.envt.fr\/masterpharmaco\/contenus-des-ue-obligatoires\/\">Continuer la lecture <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-22","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/physiologie.envt.fr\/masterpharmaco\/wp-json\/wp\/v2\/pages\/22","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/physiologie.envt.fr\/masterpharmaco\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/physiologie.envt.fr\/masterpharmaco\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/physiologie.envt.fr\/masterpharmaco\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/physiologie.envt.fr\/masterpharmaco\/wp-json\/wp\/v2\/comments?post=22"}],"version-history":[{"count":0,"href":"https:\/\/physiologie.envt.fr\/masterpharmaco\/wp-json\/wp\/v2\/pages\/22\/revisions"}],"wp:attachment":[{"href":"https:\/\/physiologie.envt.fr\/masterpharmaco\/wp-json\/wp\/v2\/media?parent=22"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}